Stay updated on Cetuximab & Nivolumab in Head & Neck Cancer Clinical Trial
Sign up to get notified when there's something new on the Cetuximab & Nivolumab in Head & Neck Cancer Clinical Trial page.

Latest updates to the Cetuximab & Nivolumab in Head & Neck Cancer Clinical Trial page
- CheckyesterdayChange DetectedLocations for Florida, Georgia, and Ohio were added, clarifying where the study is conducted. The revision is updated to v3.3.3 and the HHS Vulnerability Disclosure link was removed.SummaryDifference0.4%

- Check8 days agoChange Detected- A new label 'Last Update Posted (Estimated)' is displayed, and the exact 'Last Update Posted' label is removed from the Study Record Dates section.SummaryDifference0.0%

- Check15 days agoChange DetectedThe updates consist of minor timestamp-related changes on the Study Details page, including addition of December 2025 entries and removal of the 'Last Update Posted (Estimated)' item. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check29 days agoChange DetectedPublication list descriptions were updated with minor wording clarifications, noting that PubMed-sourced publications are automatically filled and may not be about the study. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check37 days agoChange DetectedAdded references to the Moffitt Cancer Center and Research Institute and a 'Helpful Links Provided by' section. Removed a government funding status notice.SummaryDifference0.5%

- Check51 days agoChange DetectedCosmetic UI/layout adjustments and an updated last-updated timestamp were observed; core study content, eligibility, locations, and enrollment remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Cetuximab & Nivolumab in Head & Neck Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cetuximab & Nivolumab in Head & Neck Cancer Clinical Trial page.